12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VX-222: Additional Phase II data

Vertex reported 24-week data from 59 treatment-naïve patients with chronic HCV genotype 1 infection who were receiving VX-222 plus Incivek telaprevir, Pegasys peginterferon alfa-2a and Copegus ribavirin in the on-going, open-label, U.S. and New Zealand Phase II ZENITH trial. Of patients who were eligible to stop all treatment at week 12, twice-daily 100 and 400 mg VX-222 resulted in respective 82% and 93% sustained viral response rates, defined as undetectable HCV RNA levels at week 12 after treatment...

Read the full 398 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >